The Cochrane Library: Cochrane Database of Systematic Reviews

DOI: 10.1002/14651858

Reviews/Protocols listed by Cochrane Review Group


  1. Cochrane Acute Respiratory Infections Group
  2. Cochrane Airways Group
  3. Cochrane Anaesthesia, Critical and Emergency Care Group
  4. Cochrane Back and Neck Group
  5. Cochrane Bone, Joint and Muscle Trauma Group
  6. Cochrane Breast Cancer Group
  7. Cochrane Childhood Cancer Group
  8. Cochrane Colorectal Cancer Group
  9. Cochrane Common Mental Disorders Group
  10. Cochrane Consumers and Communication Group
  11. Cochrane Cystic Fibrosis and Genetic Disorders Group
  12. Cochrane Dementia and Cognitive Improvement Group
  13. Cochrane Developmental, Psychosocial and Learning Problems Group
  14. Cochrane Drugs and Alcohol Group
  15. Cochrane Effective Practice and Organisation of Care Group
  16. Cochrane ENT Group
  17. Cochrane Epilepsy Group
  18. Cochrane Eyes and Vision Group
  19. Cochrane Fertility Regulation Group
  20. Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group
  21. Cochrane Gynaecology and Fertility Group
  22. Cochrane Haematological Malignancies Group
  23. Cochrane Heart Group
  24. Cochrane Hepato-Biliary Group
  25. Cochrane HIV/AIDS Group
  26. Cochrane Hypertension Group
  27. Cochrane IBD Group
  28. Cochrane Incontinence Group
  29. Cochrane Infectious Diseases Group
  30. Cochrane Injuries Group
  31. Cochrane Kidney and Transplant Group
  32. Cochrane Lung Cancer Group
  33. Cochrane Metabolic and Endocrine Disorders Group
  34. Cochrane Methodology Review Group
  35. Cochrane Movement Disorders Group
    1. About this group
    2. Reviews
      1. Acupuncture for restless legs syndromeReview
      2. Alprazolam for essential tremorReview
      3. Amantadine for dyskinesia in Parkinson's diseaseReview
      4. Amantadine in Parkinson's diseaseReview
      5. Anti-hypertensive drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies and clinical trialsReview
      6. Anticholinergics for symptomatic management of Parkinson´s diseaseReview
      7. Beta-blocker therapy for tremor in Parkinson's diseaseReview
      8. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE)Review
      9. Botulinum toxin for masseter hypertrophyReview
      10. Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsyReview
      11. Botulinum toxin type A therapy for blepharospasmReview
      12. Botulinum toxin type A therapy for cervical dystoniaReview
      13. Botulinum toxin type A therapy for hemifacial spasmReview
      14. Botulinum toxin type A versus anticholinergics for cervical dystoniaReview
      15. Botulinum toxin type A versus botulinum toxin type B for cervical dystoniaReview
      16. Botulinum toxin type B for cervical dystoniaReviewNew Search
      17. Bromocriptine for levodopa-induced motor complications in Parkinson's diseaseReview
      18. Bromocriptine versus levodopa in early Parkinson's diseaseReview
      19. Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's diseaseReview
      20. Cabergoline for levodopa-induced complications in Parkinson's diseaseReview
      21. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's diseaseReview
      22. Cannabinoids for Tourette's SyndromeReview
      23. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's diseaseReview
      24. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's diseaseReview
      25. Coenzyme Q10 for Parkinson's diseaseReview
      26. Comparison of speech and language therapy techniques for speech problems in Parkinson's diseaseReview
      27. Constraint-induced movement therapy in the treatment of the upper limb in children with hemiplegic cerebral palsyReview
      28. Creatine for Parkinson's diseaseReview
      29. Dopamine agonist therapy in early Parkinson's diseaseReview
      30. Dopamine agonists for the treatment of restless legs syndromeReview
      31. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complicationsReview
      32. Helicobacter pylori eradication for Parkinson's diseaseReview
      33. Interventions for drooling in children with cerebral palsyReview
      34. Interventions for fatigue in Parkinson's diseaseReview
      35. Intrathecal baclofen for treating spasticity in children with cerebral palsyReview
      36. Iron for restless legs syndromeReview
      37. Levodopa for the treatment of restless legs syndromeReview
      38. Lisuride for levodopa-induced complications in Parkinson's diseaseReview
      39. Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's diseaseReview
      40. Monoamine oxidase B inhibitors for early Parkinson's diseaseReview
      41. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's diseaseReview
      42. Non-pharmacological therapies for dysphagia in Parkinson's diseaseReview
      43. Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studiesReview
      44. Occupational therapy for patients with Parkinson's diseaseReview
      45. Pergolide for levodopa-induced complications in Parkinson's diseaseReview
      46. Pergolide versus bromocriptine for levodopa-induced complications in Parkinson's diseaseReview
      47. Pharmacotherapy for sleep bruxismReview
      48. Physiotherapy for Parkinson's disease: a comparison of techniquesReview
      49. Physiotherapy versus placebo or no intervention in Parkinson's diseaseReview
      50. Pimozide for tics in Tourette's syndromeReview
      51. Pramipexole for levodopa-induced complications in Parkinson's diseaseReview
      52. Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's diseaseReview
      53. Ropinirole for levodopa-induced complications in Parkinson's diseaseReview
      54. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's diseaseReview
      55. Speech and language therapy versus placebo or no intervention for speech problems in Parkinson's diseaseReview
      56. Speech therapy for children with dysarthria acquired before three years of ageReview
      57. Surgical treatment for the thumb-in-palm deformity in patients with cerebral palsyReview
      58. Therapeutic interventions for disease progression in Huntington's diseaseReview
      59. Therapeutic interventions for symptomatic treatment in Huntington's diseaseReview
      60. Therapies for depression in Parkinson's diseaseReview
      61. Treadmill training for patients with Parkinson's diseaseReview
      62. Whole-body vibration training for patients with neurodegenerative diseaseReview
    3. Protocols
      1. Acupuncture for children with cerebral palsyProtocol
      2. Adenosine A2A receptor antagonist istradefylline for levodopa-induced complications in Parkinson's diseaseProtocol
      3. Anticonvulsants for restless legs syndromeProtocol
      4. Antiepileptic drugs for Tourette's syndromeProtocol
      5. Atypical Antipsychotics for Tourette's SyndromeProtocol
      6. Benzodiazepines for restless legs syndromeProtocol
      7. Beta blockers for essential tremorProtocolWithdrawn
      8. Botulinum A toxin for focal hand dystoniaProtocolWithdrawn
      9. Botulinum toxin A for the prevention of hip dislocation in cerebral palsyProtocol
      10. Botulinum toxin type A and serial casting versus botulinum toxin type A or serial casting in treating equinus gait of children with cerebral palsyProtocol
      11. Botulinum toxin type A formulations in focal dystoniasProtocol
      12. Deep brain stimulation of subthalamic nucleus for Parkinson's diseaseProtocolComment
      13. Electrical stimulation therapy for children with cerebral palsyProtocol
      14. Interventions for improving medication adherence in patients with idiopathic Parkinson's diseaseProtocol
      15. Interventions for preventing falls in Parkinson's diseaseProtocol
      16. Mind-body movement therapies for Parkinson's diseaseProtocol
      17. Non-ergot dopamine agonists and the risk of heart failure and other adverse cardiovascular reactions in Parkinson's diseaseProtocol
      18. Opioids for restless legs syndromeProtocol
      19. Penicinillamine for Wilson's diseaseProtocol
      20. Piribedil for levodopa-induced complications in Parkinson's diseaseProtocol
      21. Piribedil for symptomatic management of Parkinson's diseaseProtocol
      22. Piribedil versus levodopa in early Parkinson's diseaseProtocol
      23. Pregabalin for essential tremorProtocol
      24. Rasagiline for levodopa-induced motor complications in Parkinson´s diseaseProtocol
      25. Riluzole for Parkinson's diseaseProtocol
      26. Riluzole for Parkinson's plus disordersProtocol
      27. Therapeutic interventions for daytime somnolence in Parkinson's diseaseProtocol
      28. Therapeutic interventions for sleep disorders in Parkinson's diseaseProtocol
      29. Topiramate for essential tremorProtocol
      30. Transcranial direct current stimulation (tDCS) for improving health -related quality of life, disability and impairment in patients with idiopathic Parkinson's diseaseProtocol
      31. Treatment of dementia in Parkinson's diseaseProtocol
      32. Treatment of psychosis in Parkinson´s diseaseProtocol
      33. Virtual reality for rehabilitation in Parkinson's diseaseProtocol
      34. Zonisamide for essential tremorProtocol
  36. Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group
  37. Cochrane Musculoskeletal Group
  38. Cochrane Neonatal Group
  39. Cochrane Neuromuscular Group
  40. Cochrane Oral Health Group
  41. Cochrane Pain, Palliative and Supportive Care Group
  42. Cochrane Pregnancy and Childbirth Group
  43. Cochrane Public Health Group
  44. Cochrane Schizophrenia Group
  45. Cochrane Skin Group
  46. Cochrane STI Group
  47. Cochrane Stroke Group
  48. Cochrane Tobacco Addiction Group
  49. Cochrane Upper GI and Pancreatic Diseases Group
  50. Cochrane Urology Group
  51. Cochrane Vascular Group
  52. Cochrane Work Group
  53. Cochrane Wounds Group

SEARCH